uniQure N.V. (QURE)
12.41
-0.71 (-5.45%)
At close: Mar 28, 2025, 3:59 PM
12.40
-0.12%
After-hours: Mar 28, 2025, 06:20 PM EDT
-5.45% (1D)
| Bid | 11.7 |
| Market Cap | 671.36M |
| Revenue (ttm) | 30.14M |
| Net Income (ttm) | -266.28M |
| EPS (ttm) | -4.73 |
| PE Ratio (ttm) | -2.62 |
| Forward PE | -4.94 |
| Analyst | Buy |
| Ask | 12.8 |
| Volume | 854,280 |
| Avg. Volume (20D) | 1,068,128 |
| Open | 13.08 |
| Previous Close | 13.13 |
| Day's Range | 12.00 - 13.08 |
| 52-Week Range | 3.73 - 19.18 |
| Beta | 0.36 |
About QURE
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phas...
Industry Biotechnology
Sector Healthcare
IPO Date Feb 5, 2014
Employees 209
Stock Exchange NASDAQ
Ticker Symbol QURE
Website https://www.uniqure.com
Analyst Forecast
According to 9 analyst ratings, the average rating for QURE stock is "Buy." The 12-month stock price forecast is $31, which is an increase of 149.70% from the latest price.
Stock ForecastsNext Earnings Release
uniQure N.V. is scheduled to release its earnings on May 6, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
2 months ago
-9.75%
UniQure shares are trading lower after the company...
Unlock content with
Pro Subscription
3 months ago
+12.99%
UniQure shares are trading higher after Stifel maintained a Buy rating on the stock and raised its price target from $12 to $32.
